US 7,504,485 B2
	Human antibodies that bind human IL-12
Jochen G. Salfeld, North Grafton, Mass. (US); Michael Roguska, Ashland, Mass. (US); Michael Paskind, Sterling, Mass. (US); Subhashis Banerjee, Shrewsbury, Mass. (US); Daniel Edward Tracey, Harvard, Mass. (US); Michael White, Framingham, Mass. (US); Zehra Kaymakcalan, Westborough, Mass. (US); Boris Labkovsky, Marlborough, Mass. (US); Paul Sakorafas, Newton, Mass. (US); Geertruida M. Veldman, Sudbury, Mass. (US); Amy Venturini, Lexington, Mass. (US); Angela Widom, Acton, Mass. (US); Stuart Friedrich, Cary, N.C. (US); Nicholas W. Warne, Andover, Mass. (US); Angela Myles, Andover, Mass. (US); John Gawain Elvin, Cambridge (United Kingdom); Alexander Robert Duncan, Cambridge (United Kingdom); Elaine J. Derbyshire, Royston (United Kingdom); Sara Carmen, Cambridge (United Kingdom); Stephen Smith, Ely (United Kingdom); Thor Las Holtet, Royston (United Kingdom); and Sarah Leila Du Fou, Hitchen (United Kingdom)
Assigned to Abbott GmbH & Co., KG, Wiesbaden (Germany)
Filed on Jul. 01, 2004, as Appl. No. 10/884,830.
Application 10/884830 is a division of application No. 09/534717, filed on Mar. 24, 2000, granted, now 6,914,128.
Claims priority of provisional application 60/126603, filed on Mar. 25, 1999.
Prior Publication US 2005/0004354 A1, Jan. 06, 2005
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/395 (2006.01)

U.S. Cl. 530—388.23  [424/145.1]

51 Claims

1. A pharmaceutical composition comprising an isolated human antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12, and further comprising an additional agent.